A new electronic implant system can help lab‑grown pancreatic cells mature and function properly, potentially providing a basis for novel, cell-based therapies for diabetes. The approach, developed by researchers at…
Breakthrough T1DSpotlight on OPF-310: A porcine-derived cell therapy in clinical trialsOne of our most promising avenues toward cures for type 1 diabetes is cell therapies. Learn more about one of…
Former Bristol Myers Squibb and Celgene executive to strengthen the Fund’s impact strategy and fuel transformative investments across innovative modalities BOSTON, Jan. 21, 2026 /PRNewswire/ — The T1D Fund: A Breakthrough…
NatureLab-made islet cell implants sail through diabetes trials, but are they ready yet?First-in-human studies provide hope that islet replacement therapies derived from stem cells will prove safe and effective in…
At the American Heart Association (AHA) 2025 Scientific Sessions in New Orleans, experts emphasized a paradigm shift toward holistic management of patients with type 2 diabetes (T2D) and chronic kidney…
Barchart.com Type 1 Diabetes Market Report 2032: Latest FDA, EMA, PDMA, Pipeline Therapies, EpidemiologyDelveInsight's “Type 1 Diabetes Market Insights, Epidemiology, Market Forecast – 2032” report provides a detailed understanding of…
Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis…
[00:00:00] Scott K. Johnson: I’m excited to introduce Stefany Shaheen, Chief Strategy Officer of Advanced Regenerative Manufacturing Institute, or ARMI. And BioFab USA, a program of ARMI. Stefany’s background is…